Latest News

Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • October 23, 2018 10:34 AM | Anonymous

    October 22, 2018, Medscape   

    A first-of-its kind phase 3 study found that patients with advanced ovarian cancer who carry a BRCA mutation have a marked increase in progression-free survival (PFS) if they are given maintenance therapy with the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib (Lynparza, AstraZeneca) following successful first-line chemotherapy. 

    Read more.

  • October 18, 2018 1:35 PM | Anonymous

    October 18,2018, Via CARDEA Services | Training, Organizational Development and Research 

    Independent Study:
    HIV Care and Sexual Health Assessment for
    American Indian and Alaska Native Patients

    Register now for the free online continuing education opportunity!

    This course will help prepare you to provide optimal HIV prevention, screening and treatment in any primary care setting. You will learn practical tips for performing a brief sexual health assessment and how to provide HIV and sexual health services in a culturally sensitive manner to people of all genders and sexual orientations. Cardea designed this four-module online learning course in partnership with the Urban Indian Health Institute, a division of the Seattle Indian Health Board (SIHB/UIHI). Each of the modules includes a written transcript of the audio/narration that is approximately 30 minutes in length.

    Who Should Attend

    This course is designed for staff who provide medical care to patients in a variety of clinical settings. While created specifically for staff who provide care for American Indian and Alaska Native patients, many of the core concepts, video-taped scenarios, and approaches are also relevant to health care providers who serve diverse patient populations. Physicians, physician assistants, nurse practitioners, nurses, medical assistants and other staff involved in patient care will benefit from this new course on conducting gender-inclusive sexual health assessment and providing HIV care.

    Registration & Fees

    This course is FREE OF CHARGE.     

    Click here to register

    Continuing Medical Education Information 

    Continuing Nursing Education (CNE)

    Cardea Services is an approved provider of continuing nursing education by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

    HIV Care and Sexual Health Assessment for American Indian and Alaska Native Patients: 3 contact hours will be awarded. This activity expires on September 30, 2020.

    Continuing Medical Education (CME)

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Institute for Medical Quality/California Medical Association (IMQ/CMA) through the joint providership of Cardea and the Urban Indian Health Institute, a division of the Seattle Indian Health Board. Cardea is accredited by the IMQ/CMA to provide continuing medical education for physicians.

    Cardea designates this internet activity enduring material for a maximum of 3 AMA PRA Category 1 Credit(s)™.Physicians should claim credit commensurate with the extent of their participation in the activity.

    Successful completion of this continuing education activity includes the following:

    • Completing the entire CE activity
    • Passing the post-test with a score of 80% or greater
    • Completing the online evaluation
    • Submitting an online CE Request

    Expiration date: This activity was originally released on October 1, 2018 and is available for continuing education credit until September 30, 2020.


    Cardea Services developed this independent study in partnership with the Urban Indian Health Institute a division of the Seattle Indian Health Board.


    Contact our Oakland office at 510.835.3700 or

  • October 18, 2018 9:22 AM | Anonymous

    October 18, 2018, The Pharma Letter 

    The U.S. Food and Drug Administration approved Talzenna (talazoparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib. 

    Read more.

  • October 18, 2018 9:20 AM | Anonymous

    October 18, 2018, HealthDay News via Medical Xpress

    American women are having fewer children, and they're having them later in life, a new government report shows. "Overall, we saw continuing decreasing trends in total fertility," said report author Danielle Ely, a health statistician at the National Center for Health Statistics (NCHS), which is part of the U.S. Centers for Disease Control and Prevention.  

    Read more.

  • October 18, 2018 9:00 AM | Anonymous

    October 18, 2018, via ACOG

    Attend the Education in Women's Genomics Counseling course on Friday, December 7, 2018 in Washington, D.C.
    This grant-based course is designed to enhance physicians' knowledge and application of genomic technologies in the fields of reproductive healthcare. 


    Learn how to solicit a family history to identify appropriate genetic screening, how to counsel a preconception and prenatal patient on new carrier screening and aneuploidy screening options, and the implications of positive and negative test results. You will be able to discuss the pros and cons of new genetic test options for patients seeking prenatal diagnostic testing and recognize and counsel patients about hereditary cancer syndromes relevant to women's health and develop an evidence-based testing strategy.


    1. Attend the didactic lecture ($99 holding fee refunded upon attendance)
    2. Complete eight online modules by April 30, 2019 (information to be provided) 
    3. Attend a three-hour lecture in person at the 2019 ACOG Annual Clinical and Scientific Meeting on May 5 or virtually up to seven days after the course
    4. Successfully complete posttest 

    Questions? Contact the genomics team at
  • October 17, 2018 1:47 PM | Anonymous

    October 17, 2018   

    Save the date for AAPA 2019 in Denver Colorado, May 18-22, 2019! 

    Plans for APAOG members include an awards reception and dinner. Meet fellow APAOG members as you come together  to learn about all things PA at AAPA 2019! 

    More information to come. Stay tuned! 

  • October 17, 2018 1:45 PM | Anonymous

    MedPage Today, October 17, 2018  

    Most examined patients with HIV who survived more than 2 years after allogeneic hematopoietic stem cell transplant (allo-HSCT) had undetectable HIV DNA and undetectable replication-competent virus, a small observational study found. 

    Read more.

  • October 17, 2018 1:43 PM | Anonymous

    Medgadget, October 17, 2018  

    GE Healthcare is unveiling its brand new Invenia Automated Breast Ultrasound (ABUS) 2.0 in the U.S. It is the only U.S. Food and Drug Administration approved "ultrasound supplemental breast screening technology," which allows for spotting of cancerous lesions within dense breast tissue, according to GE. 

    Read more.

  • October 12, 2018 9:04 AM | Anonymous

    October 12, 2018, The Daily Telegraph  

    Women could be spared the heartbreak of miscarriage thanks to artificial intelligence that can help to spot which pregnancies will fail. The breakthrough works with IVF treatment, using a super-computer to pick out "good" embryos — or "bad" ones, which could prevent a woman from giving birth or cause her to miscarry.

    Read more.

  • October 10, 2018 7:38 AM | Anonymous

    October 10, 2018, News Medical 

    The proportion of breast cancer patients who are eligible for breast conservation therapy, yet opt for mastectomy, is increasing, for reasons that include the desire to eliminate future screening and/or biopsy of the remaining breast tissue. A new study led by researchers at the Icahn School of Medicine at Mount Sinai has determined that having a mastectomy does not completely eliminate the need for further breast imaging studies.  

    Read more.

Powered by Wild Apricot Membership Software